All current pipeline products have been developed by Dr. Peter F. Kador and are licensed to Therapeutic Vision, Inc. All have United States and International patent coverage.
Kinostat is a topical aldose reductase inhibitor that is anticipated to receive FDA approval in the Winter 2016 / Spring 2017. FDA toxicological approval was received in Spring, 2015 and the multi-centered clinical trial was completed in January, 2016.
Multifunctional antioxidants (MFAOs) possess a novel 2-diacetylamino-5-hydroxypyrimidine moiety that independently quenches free radicals and selectively modulates redox active iron, copper, and zinc. When orally administered, the MFAOs attain therapeutic levels in the lens, neural retina, and CNS.
In studies, MFAOs protect the lens against reactive oxygen species (ROS) generated by gamma-irradiation, UV light, and endoplasmic reticulum (ER) stress. In a model for dry age-related macular degeneration (AMD), MFAOs protect against photoreceptor loss and retinal oxidation by light-induced ROS. In Alzheimer’s studies, MFAOs prevent the accumulation of Aβ plaque in the lens, retina and brain.
Current Experimental Studies
MFAOs are actively being investigated for their ability to protect the retina from traumatic insult (bomb blast) in collaboration with Dr. Steven Fliesler of the SUNY Buffalo and against noise and age induced hearing loss in collaboration with Dr. Richard Salvi of SUNY Buffalo.
Topical Nutraceutical Antioxidant Formulation
Oxidative stress increases with age and is linked to ocular problems that include dry eye, cataract, glaucoma and retinal degeneration. Our unique topical antioxidant formulation supports eye health by combining four nutraceuticals (astaxanthin, resveratrol, ethyl pyruvate and epigallocatechin gallate (EGCG)) that have antioxidant, anti-inflammatory, and chelating activity in a carbomer gel carrier. Studies show that this formulation can delay the development of cataracts and dry eye.